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Abstract
Chronic Lymphocytic Leukemia (CLL) is one of the most common forms of adult
leukemia in North Americans. However, it has been shown through the analysis of
clinical studies and synopses of medical research that no current treatment indefinitely
cures CLL or prolongs the life of CLL patients. Current CLL therapies are either
symptomatic treatments (chemotherapy and immunotherapy) that do not improve
complete remission rates or effective treatments that target the actual cancer but have
excessive morbidity and toxicity rates (stem cell transplants). Conventional CLL
treatments are inadequate according to the results of clinical trials and research of field
experts. Potential fields of research (nanotechnology, gene therapy and phytotherapy)
that show promise as CLL therapies according to the studies of researchers and scientists
should be further examined. If a cure for CLL is to be found, the focus of treatment
needs to move away from symptomatic relief toward the identification and remedy of the
cause of the cancer.
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Analysis of Current and Potential Treatment for Chronic Lymphocytic Leukemia
Background
Chronic Lymphocytic Leukemia (CLL) is one of the most prevalent blood cancers
among North American adults (Yee & O’Brien, 2006). It is a leukemia that originates in
the bone marrow with the lymphoid line of cell development. Unlike cancers typified by
amassed tissue tumors (carcinomas, sarcomas, lymphomas), leukemias are accumulations
of single, hematopoietic cells in the bloodstream or lymph. (Kindt, Goldsby & Osborne,
2007). Generic cells (hematopoietic stem cells) mature into either myeloid or lymphoid
ancestral cells from which all other specialized cells arise. Leukemias occur when there
is a malfunction in the lymphoid lineage from which natural killer cells, T cells, B cells
and dendritic cells are derived.
CLL lymphocytes develop from normal B lymphocytes (Chiorazzi, Rai, &
Ferrarini, 2005). When CLL is present, mutated lymphocytes that cannot perform their
disease-fighting role reproduce uncontrollably. They populate the bone marrow then
build up in the bloodstream, hindering the production of other cells. The numerous
lymphocytes also cause the spleen and lymph nodes to enlarge.
Currently there is no cure for CLL (Hamblin, 2001). Generally, CLL is treated
with chemotherapy which has side effects that can be as devastating as the disease itself.
Healthy Immune System
There are two arms to the human immune system: innate (natural, inherited and
nonspecific) and adaptive responses (Kindt et al., 2007). CLL is thought to have its
origins in the adaptive component of the immune system which consists of a highly
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specific detection and removal of foreign invaders (Chiorazzi et al., 2005). Adaptive
immunity is characterized by an ability to recognize and remember these foreign
antigens. The adaptive immune system also discriminates between foreign and body
cells and between varieties of antigens.
The main agents of adaptive immunity are white blood cell lymphocytes.
Normally, generic stem cells propagate along the lymphoid line of development to
become one of three types of specialized lymphocytes:
Natural killer (NK) cells are nonspecific immune cells that belong to the natural
innate immune system (Coleman, 2010; Kindt et al., 2007). They lack specialized
surface molecules that would allow for antigen-specific responses. Instead, NK cells
detect general anomalies associated with infection like abnormal numbers of a type of
surface proteins (MHC, major histocompatability complex). Defective cells are then
eliminated by the natural killer cell attaching to its surface antibodies and releasing
membrane-compromising substances.
The other two types of lymphocytes in the lymphoid lineage are part of the highly
specific adaptive immune system, with cell surface proteins that enable antigen-specific
recognition and response (Coleman, 2010; Kindt et al., 2007). T cells recognize specific
antigens only when their matching antigen is attached to another cell’s MHC (cell-surface
proteins that present antigen). There are three types of T cells which become either
active or memory T cells upon encountering their antigen in conjunction with an MHC.
In activated form, T helper (TH) cells secrete cytokine signalling proteins to induce
response of other immune agents or function as long-lasting memory cells. Upon antigen
exposure, Cytotoxic T (TC) cells become memory cells or cytotoxic T lymphocytes
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(CTLs) which eliminate cells presenting antigen on their MHC. T regulatory (Treg) cells
down-regulate the immune system when activated, playing a repressive role.
The other type of lymphocyte, B cells, produce proteins specific to a certain
foreign antigen and present these antibody proteins on their cell surface (Coleman, 2010;
Kindt et al., 2007). When the matching antigen binds to its membrane antibody, a B cell
undergoes heightened reproduction. The progeny clones become specialized plasma or
memory B cells with the same antigen specificity as the parent B cell. Plasma cells
create a secreteable form of the original B cell antibody. Memory B cells are long-lasting
clones involved in immune response if the same antigen is encountered again. B cells are
the lymphocytes that are central to CLL.
The site of B cell origination and maturation is the bone marrow (Chiorazzi et al.,
2005). Here, genetic rearrangement takes place, yielding B cells with different
membrane antibodies that function as antigen receptors. These B cell receptors are made
up of two polypeptide chains (heavy and light) with constant regions and variable
antigen-binding regions that are varied by this genetic process. The result is a population
of B cells, each with its own set of antibody surface receptors, specific for binding
different foreign antigens.
Encounters between these mature B cells and their antigens take place within the
lymph system (Coleman, 2010; Nester, Anderson & Roberts, Jr., 2007). Fluid full of
mature lymphocytes (lymph) circulates through lymphatic vessels, tissues, organs like the
spleen, and lymph nodes. Lymph nodes act as filters, bringing invading antigens or
malfunctioning host cells and B cells in contact in order for binding to stimulate B cell
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activation and consequent immune response. CLL is thought to develop from antigenactivated B cells (Chiorazzi et al., 2005).
B cell activation requires both the binding of the B cell receptor’s specific antigen
and an authorization signal from an active TH (Nester et al., 2007). When an antigen
binds to its matching B cell receptor, it gets taken into the B cell and broken down. The
B cell then displays pieces of the antigen on its cell surface MHC. If a TH receptor
recognizes the antigen, it will signal the presenting B cell to proceed with production of a
population of clone B cells (proliferation). During this reproduction, DNA undergoes
genetic rearrangements that affect the antigen-binding of the clones’ antibodies (Kindt et
al., 2007). Clones with reduced antigen binding are apoptotically eliminated while those
with high affinity antibodies can become specialized plasma cells or Memory B cells.
The short-lived plasma cells mass produce and release free-floating antibodies
which recognize the same antigen as the membrane-bound antibody of the parent B cell
(Nester et al., 2007; Kindt et al., 2007). Plasma-secreted antibodies bind the encountered
antigen and aid agents of the immune system like phagocytes, and cytotoxic NK cells to
perform their roles in antigen destruction and removal.
Newly-formed plasma cells all emit IgM class serum antibodies (Kindt et al.,
2007). However, many plasma cells undergo genetic rearrangements in the constant
regions of their antibodies in order to elicit a location-appropriate immune response. A
switch in the type and function of antibody produced occurs while maintaining the
variable region and specificity of binding for the original antigen stimulator (Kindt et al.,
2007; Nester et al., 2007). For example, tissue membrane plasma cells often switch from
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producing serum IgM to secreting more appropriate mucosal IgA antibody with the same
antigen specificity.
Memory B cells (longer-lived B cell clones) develop after differentiation and any
antibody class switching has occurred. These B cell clones are involved upon
consecutive exposure to an antigen and enable a more rapid, effective secondary immune
response.
CLL Immune System
Phenotype and development. In its most basic form, cancer is characterized by
abnormal cells that are able to escape immune screening, multiply and form groups
(Coleman, 2010). CLL is no exception. The diagnostic phenotype of CLL is the buildup
of a population of mature B cells with a certain class of surface markers (CD5+) and low
levels of IgM and IgD surface antibodies (Dighiero, et al., 1998; Keating et al., 2003). A
small number of these CLL cells are at a replicative stage while most are stopped at a
non-reproductive stage in the cell cycle. CLL cells have proteins that increase antiapoptosis mechanisms and decreased levels of apoptotic proteins (BCL-2 and BCL-X ,
respectively).
There are many factors that may give clues as to the nature of the origin of CLL.
CLL is more frequent in the elderly and two times more frequent in men (U.S. News &
World Report, 2008). Those of Asian descent are at a much lower risk for the disease
and there is a familial tie. CLL is not considered a heritable disease but the
predisposition for CLL is thought to be inherited. However, it has yet to be determined
which of these factors are relevant to the cause of CLL.
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Fluorescence in situ hybridization has detected genetic anomalies in a majority of
CLL patients but a single gene or genes that undisputedly cause CLL have yet to be
found (American Cancer Society, 2007). CLL patients often received mutations from a
parent that increased their risk of developing CLL but did not directly cause the disease.
Genetic predisposition and the resulting population of precursor CLL B cells are thought
to play a role in the development of CLL (Montserrat & Moreno, 2008). However,
precursor monoclonal B cells are present in a percentage of the healthy population so
further mutation events that trigger CLL must occur after birth for the disease to develop.
The trigger event for CLL development is thought to begin with foreign or self
antigen stimulation and subsequent clonal expansion of a genetically predisposed B cell
(Chiorazzi et al., 2005; Lanasa, 2010). A number of CLL patients show similarities in
antigen-receptors on their CLL B cells, indicating that a certain group of antigens may be
responsible for the propagation of pre-CLL cells and development into CLL. CLL cells
have multiple antigen binding sites so the trigger event could involve foreign antigens,
self antigens or combination stimulation.
Antigen activation followed by random mutations that provide survival
advantages and continual antigen encounter can select for a pre-CLL B cell (Montserrat
& Moreno, 2008). A majority of these cells are stopped by cell cycle checkpoints for
defects but a small percentage makes it through to reproduce without the mechanisms
necessary for apoptosis. If genetic mutations and other external and cellular events
provide survival advantages, a CLL cell that avoids apoptotic immune response can
propagate.
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A variety of cell components are associated with CLL cell immune system
avoidance and survival (Chiorazzi et al., 2005). CLL cells act both offensively and
defensively against apoptosis. The presence of BCL-2 proteins on CLL cells increases
anti-apoptotic mechanisms and decreased levels of apoptotic BCL-X reduce programmed
cell death mechanisms. Traditionally, CLL has been attributed only to lack of apoptosis
since most CLL cells in circulation are not at the replicative stage in the cell cycle
(Lanasa, 2010). However, a small number of these CLL cells are undergoing replication
and other characteristics like CD markers associated with activation suggest that CLL
cells may have increased cloning abilities in addition to decreased apoptosis. Without
regular controlled cell death, CLL cells are able to avoid normal eliminating immune
responses and reproduce uncontrollably.
A number of external factors also promote the survival and propagation of CLL B
cells (Montserrat & Moreno, 2008). T cell levels in CLL patients are significantly
increased in number but decreased in diversity. T-cell populations are shifted toward a
decrease in immune response. T cells associated with immune suppression (Treg) are
enabled to survive by the same anti-apoptotic BCL-2 protein as CLL cells. This results in
longer surviving suppressive Treg cells which may partially explain why CLL cells are
able to escape the immune system.
CLL cells are also protected by a microenvironment of cells and substances that
provide the necessary signals, nutrients and processes for survival (Keating et al., 2003).
Included in these supportive cells are CLL blood nurselike cells which attach and
congregate CLL cells, shielding them from therapeutic drugs. Mesenchymal stromal
cells provide a vascular system to the CLL cells (Lanasa, 2010). Cell signal cytokines

TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA

11

and chemokines that serve as clonal expansion promoters and are transmitted by direct
contact, signal delivery and antigen presentation by the cells of the microenvironment.
Symptoms. When CLL is present, mutated B cells that cannot perform their
disease-fighting role reproduce uncontrollably (Mayo Clinic, 2010). CLL cells populate
the bone marrow then build up in the bloodstream and lymph system. This results in a
variety of health complications.
Lymph nodes and spleen enlarge from CLL cell buildup. Accumulation in the
bone marrow hinders the production of other cells and causes serious health problems.
Decreased red blood cell production leads to anemia and associated symptoms. Low
platelet levels result in increased bruising, bleeding and hemorrhage. Low white blood
cell levels make CLL patients critically vulnerable to infection.
As previously mentioned, high levels of suppressive T cells are characteristic of
CLL. Consequently, CLL patients face a much greater possibility of infection (Coleman,
2010). T-cells which normally help B-cells produce antibodies can malfunction, causing
the immune system to attack the body rather than invading cells (autoimmunity).
CLL is a cancer that is attributed to the buildup of a specific type of mature B
lymphocytes in the blood, bone marrow and lymphatic system. The leukemia is thought
to develop from normal, mature B cells as a result of a combination of events and factors.
Genetic predisposition, antigenic encounter and cellular and environmental survivalpromoting factors are thought to lead to the survival and growth of CLL B cell
populations. While much information on CLL characteristics, symptoms and progression
is available, scientists have yet to discover the root cause that initiates development of the
disease.
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Current Therapies
Chemotherapy
Chemotherapy is a leukemia treatment that uses drugs to stop cell division
(National, 2007). There are different types of chemotherapy, each with its own target and
goal. Some aim to wipe out the cancer while others try to stop cancer from progressing
while treating any symptoms. (Rai, Keating, Larson & Connor, 2005)
The main focus of CLL chemotherapy has tended to be symptomatic relief with
the lowest risk of health complications from treatment since there has not yet been a
chemotherapy treatment demonstrated to result in longer life of patients.
Complete remission (CR) is a term used to describe a state of cancer-free blood
and bone marrow as well as normalized blood counts (Wierda, 2006). This state is
associated with longer survival than partial or no remission in response to therapy. The
goal of chemotherapy in regards to CLL is to obtain high rates of CR in patients and
extend remission as long as possible in hopes that overall survival (OS) rates will also
increase.
Alkylating agents (Chlorambucil). Alkylating agents result in some
symptomatic improvement, but not all symptoms disappear completely and survival is
not prolonged. Comparative studies affirm this information with partial response rates as
high as 72% but chances of complete remission as low as 4% (Palma et al., 2006).
Alkylating agents are a group of drugs that hinder the process of cell replication
(Encarta World English Dictionary, 2007). They modify DNA by inserting an alkyl
hydrocarbon group. When this group is present, the double helix DNA cannot unwind.
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As a result, the targeted cells cannot reproduce and eventually die. (American, 2007;
Hamilton, 2005).
Chlorambucil, which is the most common alkylating drug for CLL, has been
shown to have an over 50% partial response rate but no significant increase in complete
cure rates (Canadian Cancer Society, 2006).
Unfortunately, the side effects of alkylating therapy overshadow the potential for
symptomatic relief (American, 2007; Hamilton, 2005). Most alkylating agents are
derivatives of poisonous substances such as mustard gas and are understandably
associated with detrimental effects. The first issue with the drugs is the nondiscriminatory nature of their treatment. Alkylating agents target all fast growing cells,
not just cancerous B lymphocytes. This leads to lowered blood cell numbers overall
(red, white, and platelets) which increases risks of infection, bleeding, bruising, anemia
and fatigue in patients. Alkylating drugs also attack intestinal cells causing queasiness,
appetite loss and vomiting. Other side effects include hair loss and mouth sores.
Alkylating chemotherapy also increases risks of secondary cancers developing
(Abbott, 2005). One clinical study treated 1384 CLL patients with alkylating
chemotherapy. The study showed a 250% increase in risk of patients developing a
second, more aggressive cancer (acute myeloid leukemia).
Alkylating chemotherapy is associated with extensive side effects including
increased risks of infection and development of additional malignancies which must be
weighed against the potential for partial symptomatic improvement. With alkylating
treatment of CLL “the quality of response is low (CR [complete response] 0%-31%) and
the duration of responses usually short (2-18 months)” (Yee & O’Brien, 2006, p. 1114).
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While partial relief of some CLL symptoms may be obtained with alkylating therapy, it
comes at a high risk of serious health complications and lowered quality of life.
Purine nucleoside analogs (Fludarabine, Cladribine). Purine analogs are a
newer form of chemotherapy drugs that work in a slightly different way with different
results from alkylator therapy (Encarta, 2007). Purine analogs act as inhibitors to DNA
replication. They either replace or inhibit CLL enzymes such as DNA polymerase which
is essential to DNA replication (Palma et al., 2006). Without such enzymes DNA
reproduction is halted and apoptosis is stimulated, killing off cells. The main purine
analogs used in CLL treatment are Fludarabine and Cladribine.
Studies show that compared to alkylator therapies, Fludarabine and Cladribine
have higher CR rates, longer periods of CLL dormancy and greater symptomatic
response. However, purine analogs show no significant improvement in overall survival
rates (Dighiero et al., 1998; Eichhorst et al., 2009).
One study tested alkylator chlorambucil and purine nucleoside Fludarabine as
monotherapies and also in combination (Wierda, 2006; Rai, Peterson & Appelbaum,
2000). The combination therapy proved too toxic and could not be continued, but
Fludarabine yielded CR rates more than 15% higher than Chlorambucil with remissions
usually lasting 25 months. However, overall survival rates were not increased in
comparison to alkylator chemotherapy trials (Rai et al., 2000; Weirda, 2006).
Also, purine analogs demonstrate a significantly greater number of side effects
than alkylator therapy (Palma et al., 2006). Fludarabine does not specifically target
cancer cells so it also kills T-cells causing the immune system to become severely
suppressed, comparable to that of an HIV/AIDS patient. The immune system can remain
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at this vulnerable state for years. With low T-cell levels, patients can develop Richter’s
Syndrome which is a more aggressive cancer that affects major areas such as the brain
and becomes lethal after 5-8 months. Post-treatment immunosuppression also leads to
high rates of infection by a variety of harmful viruses, bacteria and fungi (Hamblin,
2001).
Fludarabine may also cause CLL to develop into a less treatable form of the
disease (Hamblin, 2001). CLL cells without a certain protein (p53) are immune to
Fludarabine. Therefore, when Fludarabine wipes out CLL cells, resistant CLL cells are
left behind that can only be treated with harsher therapies that have increased risks of
infection and other severe side effects.
The risks of getting deadly hemolytic anemia (red blood cell shortage), slowed
blood cell production, painful shingles herpes and other serious problems are high with
Fludarabine (Hamblin, 2005; Abbott, 2005).
Other purine analogs like Cladribine and Pentostatin show similar or poorer
results (Kay, Hamblin, Jelinek, Dewald, Byrd, Farag, Lucas & Lin, 2002). Purine
analogue chemotherapy has a long list of side effects including bone marrow suppression,
severely low lymphocyte, platelet and neutrophil levels, immunosuppresion associated
with secondary malignancies and high rates of infection by a variety of opportunistic
pathogens (Hamblin, 2001).
With increased risk of immuno- and myelosuppression, infection, anemia,
secondary cancers and CLL mutations, alkylating agents provide temporary symptomatic
relief but also increase chances of detrimental health problems and ultimately, shortened
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life (Byrd, 2006). Purine analog therapy may yield higher response rates than alkylator
therapy but it also shows increased severity and occurrence of negative side effects.
It is clear that chemotherapy adds more health problems to the already heavy load
CLL patients bear. Chemotherapy can provide temporary symptomatic relief but no
increase in overall survival. It increases chances of developing serious health
complications that can decrease survival length of patients. As a result it can be
concluded that treatment based on chemotherapy is not the source of a cure for CLL
(Byrd, 2006).
Immunotherapy-Monoclonal antibodies (Alemtuzumab, Rituximab). The main
immunotherapy used to treat CLL is synthetic monoclonal antibodies (Kindt et al., 2007).
Monoclonal antibodies (MABs) are antibodies specific for a single B cell clone that has
responded to one particular binding site (epitope) of an antigen. MABs are synthesized
by the replication of an artificial cell in vitro and employed in order to boost the immune
response of a CLL patient (National, 2007).
In the case of CLL, MABs are made to identify and lock onto CLL cells or cells
of specific substances that allow CLL cells to survive (National, 2007). The immune
system is then able to target and eliminate these cells. Locked-on MABs can also work
to block the growth, reproduction and spread of CLL cells. Another possible method is
for MABs to deliver toxic compounds exclusively and directly to CLL cells. MABs are
thought to induce cell death of CLL by direct drug transport, immune response
stimulation, limiting supply of needed substances, or blocking reproduction.
The two major MABs in CLL treatment are Alemtuzumab and Rituximab.
Alemtuzumab is an antibody against the CD52 surface proteins found on almost all
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mature lymphocytes (Flynn & Byrd, 2000; Kay et al., 2002; Hale et al., 1983). This
antibody locks on to B cells and facilitates cell lysis, wiping out all CLL cells while
leaving immature stem cells unharmed. In vitro tests have shown Alemtuzumab is
associated with nearly complete elimination of lymphocytes.
Rituximab is another MAB against the CD20 surface markers found on precursor
and mature B cells (Cataland, Lucas & Byrd, 2005). Rituxmab attaches to CLL B cells
which recruits immune agents involved in cell lysis or induces B cell apoptosis (National,
2007; Shaw, Quan & Totoritis, 2003).
Overall, MABs are not successful as a monotherapy. In a clinical study,
Alemtuzumab was injected into 38 CLL patients over a period of 18 weeks.
Alemtuzumab was found to have a 19% Complete Response rate (Lundin et al., 2002).
Rituximab was shown to have even lower CR rates (4%) when tested as a
monotherapy in a trial of 44 untreated CLL patients (Hainsworth et al., 2003).
In addition to the low CR rates, both antibodies present health complications. In
the Alemtuzumab trial all but 10 % of patients experienced some sort of skin reaction.
21% of patients experienced a significant drop in white blood cell levels and 10% had
cytomegalovirus develop as a result of treatment (Lundin et. al., 2002). Alemtuzumab is
also known to cause Epstein-Barr virus, cytomegalovirus, immunosuppression and high
infection rates, cytokine release syndrome, and neutropenia (Abbott, 2005; Kay et. al.,
2002).
Rituximab showed much reduced side effects associated with a clinical trial. Two
out of forty four patients showed high grade toxicity from treatment (Hainsworth et al.,
2003). However, Rituximab therapy is associated with high infection rates of fungus and

TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA

18

bacteria, Herpes Simplex and pneumocystis (Abbott, 2005). There are significant
therapy-associated risks for Complete Remission rates of only 19% and 4%, respectively.
Alemtuzumab and Rituximab have been added to other treatment regimens in
hopes of enhancing their effects since they do not fair very well on their own (Byrd,
2006). They are employed as clean up treatments to get rid of any residual CLL cells that
might be left behind after chemotherapy treatment. This approach seems to be more
successful than MABs as monotherapies.
Clinical studies have tested Rituximab with Fludarabine and Cyclophosphamide,
(alkylating agent) to create a combination treatment (FCR). One trial of 75 CLL patients
resulted in a rate of 70% for complete responses that lasted for four years in 69% of the
patients (Keating et. al., 2005). However, over half of patients in the trial developed a
high level of neutropenia, one third acquired infections and 10% came down with fevers.
Also, MABs killed off cells so rapidly that the accumulation of dead cells overloaded the
kidneys.
Another trial of FCR showed 25% rates of CR in 177 patients undergoing relapse
after treatment (Kay et al, 2002; Wierda et al., 2005). Twelve patients showed
improvement at the bone marrow level. However, toxicity of treatment was high. Minor
issues like fever, chills, hypotension, nausea and vomiting were common. Over half the
patients developed high grade neutropenia. High grade thrombocytopenia and anemia
and numerous cases of minor and major infections were observed in patients.
Furthermore, while the use of MABs has shown up to 70% CR rate, it has not actually
been shown to extend overall survival time of patients (Byrd, 2006).
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Monoclonal antibodies are supplementary treatments that add a few percent to CR
rates of chemotherapy regimens. However, MABs also add their own list of negative
side effects to those of chemotherapy. Once again a CLL therapy that treats symptoms
well does not achieve the greater goal of prolonging life.
Bone Marrow or Stem Cell Transplants
Chemotherapies are potent drugs that harm cells and tissues that demonstrate
rapid division, including bone marrow (American, 2007). Marrow is attacked severely
by chemotherapy to the point of blood cell depletion and major organ damage. Though
chemotherapy can be more effective against CLL in higher doses, the side effects will not
allow it.
Bone marrow or stem cell transplants (BMT, SCT) are used alongside
chemotherapy as a way of salvaging the bone marrow (Rai et al., 2005). The process
starts with administration of high doses of chemotherapy to CLL patients which cleans all
stem cells out of the bone marrow. Then supplies of disease-free stem cells are
transplanted, replenishing the blood supply.
Autologous SCT. With autologous transplantation, patients act as their own
donor and have their own stem cells removed before chemotherapy (Canadian, 2006).
These stem cells are cleaned of disease and preserved through freezing. After the high
dosage chemotherapy, the purified stem cells are thawed and transplanted back into the
patient.
Autologous transplants, or autografts, have not been shown to have superior
survival rates to those of conventional therapies (American, 2007). A number of studies
have concluded that autografts should not be recommended for treatment of CLL.
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One such study treated 20 evaluable patients, 50% of which came out with
progression-free survivals (Abbott, 2005; Khouri, Keating, Saliba & Champlin, 2002).
There was an overall survival rate of 78%, and 80% of patients had complete molecular
remissions. However, the majority of patients relapsed; the rate of second malignancy
development was 8%, and high instances of serious infection were recorded. It was
concluded that autologous stem cell transplantation did not provide an increase in overall
survival rates.
In another study it took three separate autografts before 12 of 38 patients
responded favorably to the treatment (Abbott, 2005). A synopsis of three autograft trials
found low mortality rates related to the transplant (1-7%), but no plateau in progressionfree survival. In other words, autografts were shown to be relatively tolerable but did not
provide complete remissions.
Secondary malignancies and syndromes are also known to develop posttransplant. Secondary malignancies developed in 21% of patients in one study (from skin
cancer to breast cancer) (Yee & O’Brien, 2006). Another study reported high chances of
Myelodysplastic Syndrome development which can turn into Acute Myeloid Leukemia
(Hamblin, 2005). All these risk factors show that autotransplantation is not a preferable
treatment for CLL (Yee & O’Brien, 2006).
Allogenic SCT. The second type of SCT is allogenic transplants or allografts
when stem cells are gleaned from a donor with a matching tissue type (preferably a
sibling) (Rai et al., 2005).
Allogenic SCT is considered to be the only therapy that can actually cure CLL
(Abbott, 2005). In contrast to Autologous SCT, allograft SCT does have a progression-
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free survival plateau with CR rates as high as 87% and is therefore considered to be a
CLL cure (Yee & O’Brien, 2006).
On the other hand, studies have shown allografts have a higher treatment related
morbidity rate of 40- 50% (Hamblin, 2005; Yee & O’Brien, 2006). This means
approximately half of patients treated with autologous SCT will die from it. One
oncologist at Sunnybrook Hospital is quoted as saying that every patient over fifty years
of age he has treated with an autograft from an unrelated donor has died within one
month (D. Spaner, personal communication, 2007).
The main fatal side effect is Graft Versus Host Disease (GVHD), commonly
known as transplant rejection (American, 2007). GVHD occurs when stem cells from a
donor create an immune response that attacks self skin, liver, intestinal tissues, mouth,
and other organs. This can result in loss of strength and energy, dry mouth, rashes and
infections, soreness in muscles and in the most severe cases, death. Other side effects of
allografts include low blood levels, vomiting, hair loss, cataracts, bone death (necrosis)
and damage to the ovaries, thyroid gland and metabolism.
A clinical trial treated 28 CLL patients with cyclophosphamide and allogenic SCT
(Khouri et al., 2002). For patients who had responded to previous chemotherapy, a 78%
OS rate was seen and progression-free survival rate of the same percent was present for 5
years. However, in all patients there was a 49% chance of acute GVHD and an 11%
morbidity rate at day 100 of treatment.
Stem cell transplants address the source of CLL by allowing for a complete
wipe-out of stem cells from the bone marrow when combined with high dosage
chemotherapy. The only problem is that neither form of SCT is ideal. Allogenic SCT
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improves CR rates significantly but is associated with very high risks of transplant
rejection and morbidity. At the other extreme, autologous SCT has much lower rates of
fatality but considerably lower response rates. So it can be concluded that stem cell
transplants are not a cure for CLL but rather treatments with weighty risks on one hand
and low success on the other.
Potential Therapies
To date, no complete cure has been found for Chronic Lymphocytic Leukemia.
Most treatments focus solely on symptoms and do not lengthen life. Other CLL therapies
aim for complete remission but in the process can have intolerable side effects. CLL
treatments have mutually exclusive results, either prolonging life with increased risk of
unbearable side effects or treating symptoms while cutting life short.
CLL research seems to have a focus on chemotherapy, chemotherapy enhancers
and chemotherapy combinations. So far, none of these have provided a desirable
outcome. Study should therefore, branch out to new areas that show promise for
potential treatment and cure of CLL.
Nanotechnology
A promising field of research for CLL therapy is nanotechnology (the
employment and manipulation of substances that are a nanometer small) (National
Cancer Institute, 2011). The hope is that a targeted method of attacking cancer cells can
be created. If a nanodevice could be made to destroy cancerous cells in an exclusive,
specialized way, a side-effect-free cure could be found. There are a number of different
nanodevices currently under investigation.
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Nanocarriers. Researchers have shown potential for nanocarriers to transport
compounds like chemotherapy drugs exclusively to malignant cells, letting noncancerous cells thrive and avoiding health risks like immunosuppresion normally
associated with drug therapies (National, 2011). Nanocarriers allow for site-specific
delivery of drugs so smaller amounts can be used and side effects lessened (Jain, 2010).
Nanocarriers also prevent drugs from dissolving before reaching target areas and aid in
delivery across membranes and barriers. Nanocarriers allow for tighter control of drug
distribution and timing and ensure the drugs actually reach their target in their most
potent form.
Passive nanocarriers are ideal for moving into tissues and building up specifically
in leaky areas that are associated with cancerous growths (National, 2011). In the case of
active nanoparticles, the cell surface make-up could cause the uptake of nanoparticles and
attached drug into the cancer cells. The hope for both these types of devices is to allow
for higher specificity and sensitivity of chemotherapy treatments by controlling drug
targeting and delivery.
Nanoshells. There is also potential for a more active role for nanodevices apart
from synthesized drugs. Nanoshells are currently under investigation for their potential
to work inside cancer cells and induce cell death by absorbing light and emitting lethal
heat (National, 2011). Cancerous cells would have to take in the nanoshells. Then light
beams of specific wavelengths would be employed and the nanoshells would generate
heat. The heat would kill off only the host cancer cells, leaving healthy cells unaffected.
This nanotechnology has actually been tested as a CLL treatment in the form of
microscopic nanoshell beads coated with gold (Mukherjee et al., 2007; National, 2007).
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In one study, the blood of CLL patients was isolated and tested for apoptosis levels in the
presence of gold nanoparticles. Out of the samples tested, 40% showed significant levels
of apoptosis of CLL B cells when just the nanoparticles were added. Higher apoptosis
rates were observed when the nanoparticles were conjugated with antibodies.
Nanotechnology is a relatively new field for CLL treatment but shows
encouraging signs of developing into a controlled therapy that could target only CLL
cells, eliminating harmful side effects seen with conventional therapies.
Gene Therapy
Another potential CLL treatment under investigation is gene therapy. There are a
number of possible ways scientists could alter the genetic makeup of a CLL patient
(National, 2007). One possibility is to exchange mutated genes for healthy ones.
Another approach is to work with the immune system. A combination of genes to
weaken cancer cells with genes to make healthy stem cells resilient would make
chemotherapy and other treatment more effective and less damaging. Finally, there is the
possibility of inserting genes into CLL cells to induce apoptosis or to hinder formation of
new cells.
Some risks are currently associated with gene therapy (National, 2007). One is
that viral vectors used to transport and transmit genes may infect all cells instead of just
diseased cancer cells. An immune reaction to the gene vectors could also occur which
would be particularly devastating for immunocompromised CLL patients. Another risk is
elevated expression with genes producing so many new cells that the body becomes
overloaded.
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Nanotechnology could play a role in creating effective genetic therapies for CLL
(Bolhassani, Safaiyan & Rafati, 2011; National, 2011). Highly-branched dendrimer
nanocarriers have been used to specifically target tumor cells for genetic therapy in mice
(Chisholm, 2009). Injected dendrimers complexed with DNA accumulated at tumors and
the attached gene was expressed specifically in tumor cells. Nanotechnology could
provide a way to control potential side effects, making gene therapy an effective, safe
CLL treatment.
Dendritic Cells
Dendritic cells are protein-sized molecules with a large surface area that present
antigens to elicit an immune response from T cells and B cells (National, 2011).
Dendritic cells are part of the protective microenvironment that supports CLL cells. A
vaccine to elicit anticancer immune response could be created from CLL-associated
antigens attached to a population of dendritic cells.
A treatment of nine patients with autologous dendritic cells recorded a decrease in
leukemic lymphocytes (Hus et al., 2005). Another clinical trial treated twelve patients
with autologous dendritic cells and five showed a decrease in the number of leukemic
cells (Hus et al., 2008).
Nanocarriers could also be injected to transmit therapeutic drugs or DNA
plasmids to dendritic cells present in the microenvironments surrounding CLL cells.
Instead of injecting a vaccine of dendritic cells, nanodevices could target dendritic cells
already in contact with CLL cells (Bolhassani et al., 2011).
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Phytotherapy
Currently under investigation are a number of natural substances known for their
anti-cancer properties. Extracts from neem tree leaf (Azadirachta indica) have been
shown to have apoptotic and preventative effects against skin cancer in animals (Arora,
Koul & Bansal, 2010). The extract is currently being employed in a CLL Phase I Trial
by the Roswell Park Institute to test its effectiveness and toxicity as a CLL treatment
(U.S. National Institute of Health, 2010).
A green tea extract has also been tested as a potential CLL treatment.
Epigallocatechin-3-gallate (EGCG) is a protein inhibitor and was used in vitro with CLL
B cells to determine the effects on cancerous cells (Lee et al., 2004). In 80% of the CLL
samples tested, ECGG caused a notable increase in apoptosis. ECGG was shown to
decrease the BCL-2 protein which is attributed with CLL cells’ ability to avoid apoptosis.
ECGG shows promise as an alternative CLL therapy or supplement to current treatments.
Finally, allicin, an extract from garlic, has been shown to have potential as
therapy against B cell cancers (Arditti et al, 2005). This substance is produced when the
enzyme allinase reacts with alliin. The allicin reaction was controlled and the allicin
product was tested against CLL cells in vitro. It was used in combination with rituximab
to target CD20+ CLL B cells. After treatment, B cell survival was reduced by 96%.
While most research as cancer therapy have been restricted to in vitro studies,
natural extracts show potential as a source of effective CLL therapies with low toxicity.
They may also one day be employed in combination with current therapies and enable
lower dosage and decreased toxicity and negative side effects.
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Summary
Conventional therapies for CLL are mostly temporary symptomatic treatments
that combat the effects of the cancer and not the malignancy itself. As a result they are
not proven to prolong life and in most cases, they add negative side effects to the disease
load of CLL patients.
Chemotherapy
Chemotherapy drugs are the most widely used CLL treatment even though they
can be highly damaging and only provide temporary relief of symptoms. Alkylator
agents have low complete response rates with partial symptomatic improvement. They
result in higher chances of secondary malignancies. Purine analogs, another group of
chemotherapy drugs, yield higher rates of symptomatic relief. However, these therapies
can result in severe immunosuppression and a CLL mutation into Richter’s Syndrome.
Biologic/ Immunotherapy
Biologic monotherapies of monoclonal antibodies do not have as many side
effects as chemotherapy but are also much less effective. When used in combination
with chemotherapy, MABs increase effectiveness but also add more side effects to the
previously mentioned risks of chemotherapy.
Bone Marrow or Stem Cell Transplant
There are two categories of stem cell transplants, both with their downsides.
Though SCT is the only CLL therapy to address the root-cause of the disease, it is still
not preferable. Allogenic stem cell transplants improve CR rates significantly but they
have high risks of transplant rejection and transplant-related death. Autologous SCT
have much lower morbidity rates but their response rates are not impressive.
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Potential Therapy
Nanotechnology shows promise for controlled therapy that could exclusively
target CLL cells and deliver drugs or heat to kill them without negative side effects.
If controlled by nanotechnology, gene therapy could manipulate DNA to weaken
cancer cells, strengthen healthy cells and boost the immune system. Gene therapy has
potential to be an effective and safe treatment of CLL.
Discoveries of natural cancer-fighting substances are being made in the field of
phytotherapy. Natural extracts could treat CLL with low associated toxicity and risk.
Conclusion
In order to find a safe, complete cure for CLL, research needs to move away from
a conventional, chemotherapy-centered focus. The symptoms and pathology of CLL are
well researched and for the most part, understood. There are also numerous known
factors that increase the risk of CLL. However, if a cure or preventative measures for
CLL are to be discovered, the cause of the disease needs to be better understood.
Researchers should further investigate individual factors and the cumulative
effects of genetic predisposition, precursor cells and antigen and chemical exposure. If
the origin of CLL remains unknown, the search for a cure will continue to be nothing
more than a hit-and-miss scenario guided by chance and not information.
Completely new areas with potential for permanent complete remission like
nanotechnology, gene therapy and phytotherapy show promise as sources for effective,
low toxicity CLL treatments. These and other safer, effective methods of treatment with
potential for consistent results of permanent, complete remission should be further
pursued.
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